

DAFTAR PUSTAKA

- Abdel-Galil SM, Ezzeldin N dan El-Boshy ME. 2015. The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. *Cytokine*, Vol. 76, No. 2, pp 280–287.
- Abdo AIK dan Tye GJ. 2020. Interleukin 23 and autoimmune diseases: current and possible future therapies. *Inflammation Research*, Vol. 69, No. 5, pp. 463–480.
- Absher DM, Li X, Waite LL, Gibson A, Roberts K, Edberg J, Chatham WW, Kimberly RP. 2013. genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell Populations. *PLoS Genetics*, Vol.9, No. 8, pp. e1003678
- Adnyana IK, Yulinah E, Maeistuti N dan Setiawan F. 2014. Evaluation of Ethanolic Extracts of Mullaca (*Physalis angulata* L .) Herbs for Treatment of Lupus Disease in Mice Induced Pristane. *Procedia Chemistry*, Vol. 13, pp. 186–193.
- Aggarwal S, Ghilardi N, Xie MH, De Sauvage FJ dan Gurney AL. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. *Journal of Biological Chemistry*, Vol. 278, No. 3, pp. 1910–1914.
- Agmon-Levin N dan Shoenfeld Y. 2016. *Systemic Lupus Erythematosus and the Environment. Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects*. Elsevier: Amsterdam, Netherlands
- Agustiarini V, Darmawan E dan Akrom A. 2019 The effects of dosage variation in black seed cumin oil (*Nigella sativa* L.) use on HbA1c levels and interleukin-17A expression in patients at risks of metabolic syndrome. *Pharmaciana*. Vol. 9, No. 2, pp. 261
- Ahmed Z, Prawiro SR dan Endharti AT. 2018. *Nigella sativa* extract increases antibacterial activity by up-regulating Treg and Th2 levels in Salmonella enterica subsp. enterica serovars Typhimurium-exposed BALB/c mice. *Research Journal of Life Science*, Vol. 5, No. 1, pp. 14–22.
- Al-Ali A, Alkhawajah AA, Randhawa MA dan Shai NA. 2009. Oral and intraperitoneal LD50 of thymoquinone, an active principle of *Nigella sativa*, in mice and rat, *Journal of Ayub Medical College, Abbottabad*. Vol. 20, No. 2, pp. 25-7.
- Albaar TM, Handono K, Poeranto S, Nurdiana, Arifin S, Hartanti KD, Gumilang R, Dharmesta NA, Saputri NV⁵, Anggita A dan Dananjaya V. 2018. Efficacy studies of Treg activation using dsDNA desensitization inhibits immune function without side effect in lupus mice model. *AIP Conference Proceeding*. Vol. 2108, No. 020037.
- Almaani S, Meara A dan Rovin BH. 2017. Update on Lupus Nephritis. *Clin J Am Soc Nephrol*, 12, 825–835.
- Al-Saleh IA, Billedo G, El-Doush II. 2006. Levels of selenium, DL- α -tocopherol, DL- γ -tocopherol, all-trans-retinol, thymoquinone and thymol in

- different brands of *Nigella sativa* seeds. *Journal of Food Composition and Analysis*. Vol. 19, pp. 167–175.
- Alunno A, Bartoloni E, Bistoni O, Nocentini G, Ronchetti S, Caterbi S, Valentini V, Riccardi C, Gerli R. 2012. Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. *Clinical of Develoemental Immunology*. Vol. 2012, pp.:82-85.
- Alvarado-Sánchez B, Hernández-Castro B, Portales-Pérez D, Baranda L, Layseca-Espinosa E, Abud-Mendoza C, Cubillas-Tejeda AC, González-Amaro R. 2006. Regulatory T cells in patients with systemic lupus erythematosus. *Journal of Autoimmunity*, Vol. 27, No. 2, pp. 110–118.
- Amarilyo G, Lourenço EV, Shi FD, dan La Cava A. 2014. IL-17 Promotes Murine Lupus. *The Journal of Immunology*, Vol. 193, No. 2, pp. 540–543.
- Andy SK dan Kandasamy E. 2018. Clinical profile of systemic lupus erythematosus among children less than 12 years. *International Journal of Contemporary Pediatrics*, Vol. 5, No. 2, pp. 343.
- Anonimus, 2017. Situasi Lupus di Indonesia, *Infodatin*, pp. 1–7.
- Arbuckle MR, James JA, Kohlhase KF, Rubertone MV, Dennis GJ dan Harley JB. 2001. Development of Anti-dsDNA Autoantibodies Prior to Clinical Diagnosis of Systemic Lupus Erythematosus. *Scandinavia Journal of Immunology*. Vol. 54, No. 1-2, pp. 211-219.
- Arbuckle MR, McClain MT, Rubertone MV, Scofield HR, Dennis GJ, James JA dan Harley JB. 2003. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. *New England Journal of Medicine*, Vol. 349, No. 16, pp. 1526–1533.
- Ari S, Kurniawati A, Faridah D dan Herlina QQ. 2017. Changes of Black Cumin (*Nigella sativa* L .) Thymoquinone , Thymol and Malondialdehyde Content in Response to Indonesia Tropical Altitude Variation, *HAYATI Journal of Biosciences*, Vol. 24, No. 3, pp. 3–7.
- Asfour W, Almadi S dan Haffar L. 2013. Ethanolic Extract of *Nigella sativa* Seeds Lacks the Chemopreventive Efficacy in the Post Initiation Phase of DMH-Induced Colon Cancer in a Rat Model. *Pharmacology & Pharmacy*, Vol. 04, No. 02, pp. 222–230.
- Asgary S, Ghannadi A, Dashti G, Helalat A, Sahebkar A, dan Najafi S, 2013. *Nigella sativa* L. improves lipid profile and prevents atherosclerosis: Evidence from an experimental study on hypercholesterolemic rabbits. *Journal of Functional Foods*, Vol. 5, No. 1, pp. 228-234.
- Assi MA, Hezmee M, Noor M, Bachek NF, Ahmad H, Haron AW, Yusoff SM, Rajion MA. (2016). The Various Effects of *Nigella sativa* on Multiple Body Systems in Human and Animals. *Pertanika Journal of Scholarly Research Reviews*, Vol. 2, No. 3, pp. 1–19.
- Badary OA, Al-Shabanah OA, Nagi MN, Al-Bekairi AM dan Elmazar MMA. 1998. Acute and subchronic toxicity of thymoquinone in mice. *Drug Development Research*, Vol. 44, No. 2–3, pp. 56–61.
- Bagavant H, Thompson C, Ohno K, Setiady Y dan Tung KSK. 2002. Differential effect of neonatal thymectomy on systemic and organ-specific autoimmune disease. *International Immunology*, Vol. 14, No. 12, pp. 1397–1406.
- Ballantine LE, Ong J, Midgley A, Watson L, Flanagan BF dan Beresford MW.

2014. The proinflammatory potential of T cells in juvenile-onset systemic lupus erythematosus. *Pediatric Rheumatology*, Vol. 12, No. 1, pp. 2–7.
- Barlianto W dan Mintaroem K. 2012. Pengaruh Sel Limfosit T Regulator CD4 CD25 Foxp3 dan Transforming Growth Factor (TGF) β terhadap Airway Remodelling Bronkiolus Paru pada Model Mencit Asma terhadap Airway. *Jurnal Kedokteran Brawijaya*, Vol. 27, No. 2, pp. 71-76.
- Barlianto W, Khotimah H. 2011. Modulasi sistem imun dan hambatan Airway Remodelling setelah pemberian ekstrak etanol Jinten Hitam (*Nigella sativa*) pada mencit model asma, Disertasi. *Universitas Brawijaya, Malang*.
- Barlianto W, Kusuma HMSC, Widodo MA dan Suharto S. 2012. Crude extract of black seed (*Nigella sativa*) can modulate T CD4+CD25+FoxP3+ lymphocytes in asthmatic mouse model. *Paediatric Respiratory Reviews*, Vol. 13, No. Supplement 1, pp. S54.
- Barlianto W, Wulandari D, Chusniyah M, Kusuma HMSC, Prawiro SR. 2018. Improvement of Th17/Treg balance and asthma control test score by *Nigella sativa* supplementation in asthmatic children : a new approach to managing asthma, *Turkish Journal of Immunology*, Vol. 6, No. 1, pp. 1–7.
- Barlianto, Nurdiana N, Dewi ES, Maya A, Pratama MZ, Handono K, Kalsum U, Syukur NA, Sari Y. 2017. Immunomodulation Effects of Bryophyllum Pinnatum on Pregnant Pristane-Induced Lupus Mice Model. *Research Journal of Life Science*, Vol. 3, No. 3, pp. 190–200.
- Bedoya SK, Lam B, Lau K dan Larkin III J. 2013. Th17 cells in immunity and autoimmunity. *Clinical and Developmental Immunology*. Vol. 2013, pp. 1-16.
- Bensiameur-Touati K, Kacimi G, Haffaf EM, Berdja S dan Aouichat-Bouguerra S. 2017. In Vivo Subacute Toxicity and Antidiabetic Effect of Aqueous Extract of *Nigella sativa*. *Evidence-based Complementary and Alternative Medicine*, Vol. 2017, pp. 1-14.
- Bertsias GK, Salmon JE dan Boumpas DT. 2010. Therapeutic opportunities in systemic lupus erythematosus: State of the art and prospects for the new decade. *Annals of the Rheumatic Diseases*, Vol. 69, No. 9, pp. 1603–1611.
- Bianchi E dan Rogge L. 2019. The IL-23/IL-17 pathway in human chronic inflammatory diseases— new insight from genetics and targeted therapies. *Genes & Immunity*. Vol. 20, No. 5, pp. 415-425.
- Biermann MHC, Veissi S, Maueröder C, Chaurio R, Berens C, Herrmann M dan Munoz LE. 2014. The role of dead cell clearance in the etiology and pathogenesis of systemic lupus erythematosus: Dendritic cells as potential targets. *Expert Review of Clinical Immunology*, Vol. 10, No. 9, pp. 1151–1164.
- Binger KJ, Côté-Real BF and Kleinewietfeld M. 2017. Immunometabolic Regulation of Interleukin-17-Producing T Helper Cells: Uncoupling New Targets for Autoimmunity. *Frontiers in Immunology*. Vol. 8, No. 331, pp. 1-18.

- Bonelli M, Savitskaya A, Von Dalwigk K, Steiner CW, Aletaha D, Smolen JS dan Scheinecker C. 2008. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). *International Immunology*, Vol. 20, No. 7, pp. 861–868.
- Bradley SJ, Tsokos GC dan Sua A. 2016. T cells in Systemic Lupus Erythematosus, *Current Opinion in Immunology*, Vol. 43, pp. 32–38.
- Bubier JA, Sproule TJ, Foreman O, Spolski R, Shaffer DJ, Morse HC et al. 2009. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. *Proceedings of the National Academy of Sciences US*. 106: 1518–1523.
- Butt MS dan Sultan MT. 2010, *Nigella sativa*: reduces the risk of various maladies. *Critical Reviews in Food Science and Nutrition*, Vol. 50, pp. 654–665.
- Calvani N, Caricchio R, Tucci M, Sobel ES, Silvestris F, Tartaglia P dan Richards HB. 2005. Induction of apoptosis by the hydrocarbon oil pristane: implications for pristane-induced lupus. *The Journal of Immunology*, Vol. 175, No. 7, pp. 4777- 4782.
- Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T dan Linnik MD. 2008. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology*, Vol. 58, No. 8, pp.2470-2480.
- Chafin CB, Regna NL, Hammond SE dan Reilly CM. 2013. Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment. *International immunopharmacology*, Vol. 17, No. 3, pp. 894-906.
- Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X dan Zhao L. 2018. Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget*. Vol. 9, No. 6, pp: 7204-7218.
- Chen Y, Cuda C dan Morel L. 2005. Genetic Determination of T Cell Help in Loss of Tolerance to Nuclear Antigens. *The Journal of Immunology*, Vol. 174, No. 12, pp. 7692–7702.
- Chowdhary VR, Dai C, Tilahun AY, Hanson JA, Smart MK, Grande JP, Rajagopalan G, Fu SM, David CS. 2015. A Central Role for HLA-DR3 in Anti-Smith Antibody Responses and Glomerulonephritis in a Transgenic Mouse Model of Spontaneous Lupus. *The Journal of Immunology*. Vol. 195, No.10, pp. 4660-4667.
- Chugh PK. 2012. Lupus: Novel therapies in clinical development. *European Journal of Internal Medicine*, Vol. 23, No. 3, pp. 212–218.
- Clark DN, Markham JL, Sloan CS dan Poole BD. 2013. Cytokine inhibition as a strategy for treating systemic lupus erythematosus. *Clinical Immunology*, Vol. 148, No. 3, pp. 335–343.
- Conti G, Coppo R dan Amore A. 2003. Pathogenesis of systemic lupus erythematosus (LES). *Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia*, Vol. 29 Suppl No. 5, pp. S84-90.
- Crispín JC, Kyttaris VC, Terhorst C dan Tsokos GC. 2010. T cells as therapeutic targets in SLE. *Nature Reviews Rheumatology*, Vol. 6, No. 6, pp. 317–325.

- Crispín JC, Liossis SNC, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, dan Tsokos GC. 2010. Pathogenesis of human systemic lupus erythematosus: recent advances. *Trends of Molecular Medicine*. Vol. 16, No. 2, pp. 47–57.
- Cunningham MA, Wirth JR, Scott JL, Eudaly J, Collins EL dan Gilkeson GS. 2016. Early Ovariectomy Results in Reduced Numbers of CD11c+/CD11b+ Spleen Cells and Impacts Disease Expression in Murine Lupus. *Frontiers in Immunology*, Vol. 7, No. 31, pp. 1-10.
- Cunningham MA, Wirth JR, Scott JL, Eudaly J, Collins EL dan Gilkeson GS. 2016. Early ovariectomy results in reduced numbers of CD11c+/CD11b+ spleen cells and impacts disease expression in murine lupus. *Frontiers in immunology*, Vol. 7, No .31, pp. 1-10.
- Dai H, He F, Tsokos GC, Kyttaris VC. 2017. IL-23 Limits the Production of IL-2 and Promotes Autoimmunity in Lupus. *The Journal of Immunology* Vol. 199, No. 3, pp. 903-910.
- Dajani ZE, Shahwan GT, dan Dajani EN. 2019. Overview of the human investigations of *Nigella sativa* (black seeds): a complementary drug with historical and clinical significance. *General Internal Medicine and Clinical Innovations*, Vol. 4, No. 1, pp. 1–16
- Davis LS dan Reimold AM. 2017. Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus. *Rheumatology (Oxford, England)*, Vol. 56, No. 1, pp. i100–i113.
- De Leeuw K, Bungener L, Roozendaal C, Bootsma H dan Stegeman CA. 2017. Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: Comparison of different assays during quiescent and active disease. *Rheumatology (United Kingdom)*, Vol. 56, No. 5, pp. 698–703.
- Deng, X. M., Yan, S. X., & Wei, W. 2015. IL-21 acts as a promising therapeutic target in systemic lupus erythematosus by regulating plasma cell differentiation. *Cellular & Molecular Immunology*, 12(1), 31-39.
- Di Caro, V., Cummings, J. L., Alcamo, A. M., Piganelli, J. D., Clark, R. S., Morowitz, M. J., & Aneja, R. K. 2019. Dietary cellulose supplementation modulates the immune response in a murine endotoxemia model. *Shock*, 51(4), 526-534.
- Dörner T, Giesecke C dan Lipsky PE. 2011. Mechanisms of B cell autoimmunity in SLE, *Arthritis Research and Therapy*, Vol. 13, No. 5, pp. 1–12.
- dos Santos M, Favero G, Bonomini F, Stacchiotti A, Rodella LF, Veronese FV, Rezzani R. 2017. Oral supplementation of melatonin protects against lupus nephritis renal injury in a pristane-induced lupus mouse model. *Life Sciences*. Vol. 193, pp. 242-251.
- Du J, Li Z, Shi J, Bi L. 2014. Associations between serum interleukin-23 levels and clinical characteristics in patients with systemic lupus erythematosus. *J Int Med Res*. Vol. 42, No. 5, pp.1123-1130.
- Dubey PN, Singh B, Mishra BK, Kant K dan Solanki RK. 2016. *Nigella sativa* L.): a high value seed spice with immense medicinal potential. *Indian Journal of Agriculture Science*, Vol. 86, No. 8, pp.967-979.

- Eilertsen G, Nikolaisen C, Becker-Merok A, Nossent JC. 2011. Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus. *Lupus*. Vol. 20, No. 6, pp. 607-613.
- El Gazzar MA. 2007. Thymoquinone suppresses in vitro production of IL-5 and IL-13 by mast cells in response to lipopolysaccharide stimulation. *Inflammation Research*, Vol. 56, No. 8, pp. 345-51.
- Elkon KB, Santer DM, Wiedeman A. 2012. Complement deficiencies and susceptibility to systemic lupus erythematosus revisited. *Arthritis Research & Therapy*. Vol. 14, No. Suppl 3, pp. A40.
- Elmowalid G, Amar AM dan Ahmad AAM. 2013. *Nigella sativa* seed extract: 1. Enhancement of sheep macrophage immune functions in vitro. *Research in Veterinary Science*, Vol. 95, No. 2, pp. 437-443.
- Elsherbiny NM, Maysarah NM, El-Sherbiny M dan Al-Gayyar MM. 2017. Renal protective effects of thymoquinone against sodium nitrite-induced chronic toxicity in rats: Impact on inflammation and apoptosis. *Life Sciences*, Vol. 180, pp. 1-8.
- Familia, A. C., Yuliasih, Y., & Rahmawati, L. D. 2019. Correlation between serum IL-6 level and Th17/Treg ratio with Systemic Lupus Erythematosus Disease Activity. *Biomolecular and Health Science Journal*, 2(2), 107-112.
- Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M dan Houssiau F, 2019. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Annals of the rheumatic diseases*, Vol. 78, No. 6, pp.736-745.
- Farhangi MA, Dehghan P, Tajmiri S dan Abbasi MM. 2016. The effects of *Nigella sativa* on thyroid function, serum Vascular Endothelial Growth Factor (VEGF) – 1, Nesfatin-1 and anthropometric features in patients with Hashimoto's thyroiditis: A randomized controlled trial. *BMC Complementary and Alternative Medicine*, Vol. 16, No. 1, pp. 1-9.
- Farhangi MA, Dehghan P, Tajmiri S, Abbasi MM. 2016. The effects of *Nigella sativa* on thyroid function, serum Vascular Endothelial Growth Factor (VEGF) - 1, Nesfatin-1 and anthropometric features in patients with Hashimoto's thyroiditis: A randomized controlled trial. *BMC Complementary and Alternative Medicine*. Vol. 16, No. 1, pp. 1-9.
- Farkhondeh T, Samarghandian S dan Borji A. 2017. An overview on cardioprotective and anti-diabetic effects of thymoquinone. *Asian Pacific journal of tropical medicine*, Vol. 10, No. 9, pp.849-854.
- Farkhondeh T, Samarghandian S, Shahri AMP dan Samini F. 2018. The neuroprotective effects of thymoquinone: a review. *Dose-Response*, Vol. 16, No. 2, pp. 1-10.
- Fasching P, Stradner M, Graninger W, Dejaco C, Fessler J. 2017. Therapeutic potential of targeting the Th17/Treg axis in autoimmune disorders. *Molecules*. Vol. 22, No. 1.
- Fatoye F, Gebrye T dan Svenson LW. 2018. Real-world incidence and prevalence of systemic lupus erythematosus in Alberta, Canada. *Rheumatology International*, Vol. 38, No. 9, pp. 1721-1726.

- Fava A dan Petri M. 2019. Systemic lupus erythematosus: Diagnosis and clinical management. *Journal of Autoimmunity*, Vol. 96, pp. 1–13.
- Ferretti C dan La Cava A, 2016. Overview of the pathogenesis of systemic supus Erythematosus, *Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects*. Elsevier: Amsterdam, Netherlands
- Finck BK, Chan B dan Wofsy D. 1994. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. *Journal of Clinical Investigation*, Vol. 94, No. 2, pp. 585–591.
- Finzel S, Schaffer S, Rizzi M dan Voll RE. 2018. Pathogenese des systemischen lupus erythematoses. *Zeitschrift für Rheumatologie*, Vol. 77, No. 9, pp.789-798.
- Fors Nieves CE dan Izmirly PM. 2016. Mortality in systemic lupus erythematosus: an updated review. *Current Rheumatology Reports*, Vol. 18, No. 4, pp. 1–7
- Freitas EC, de Oliveira MS dan Monticielo OA. 2017. Pristane-induced lupus: considerations on this experimental model. *Clinical Rheumatology*, Vol. 36, No. 11, pp. 2403–2414.
- Gao, Y., Xu, X., Feng, J., Ma, Y., Zheng, D., Meng, Y., & Shan, F. 2016. Effects of interleukin-1 receptor-associated kinase 1 RNA interference in dendritic cells on inflammatory cytokine release and T-cell proliferation. *Molecular Medicine Reports*, 14, 5685-5692.
- Gerli R, Nocentini G, Alunno A, Bocci EB, Bianchini R, Bistoni O dan Riccardi C. 2009. Identification of regulatory T cells in systemic lupus erythematosus. *Autoimmunity Reviews*, Vol. 8, No. 5, pp. 426–430.
- Ghahramanloo KH, Kamalidehghan B, Javar HA, Widodo RT, Majidzadeh K, Noordin MI. 2017. comparative analysis of essential oil composition of Iranian and Indian *Nigella sativa* l. extracted using supercritical fluid extraction and solvent extraction. *Drug Design, Development and Therapy*, Vol. 7, No. 11, pp. 2221–222.
- Ghannadi A, Hajhashemi V dan Jafarabadi H. 2005. An investigation of the analgesic and anti-inflammatory effects of *Nigella sativa* seed polyphenols. *Journal of Medicinal Food*, Vol. 8, No. 4, pp. 488–493.
- Ghodke-Puranik P dan Niewold TB. 2015. Immunogenetics of systemic lupus erythematosus: A comprehensive review. *Journal of Autominune*. Vol. 64, pp. 125-3.
- Gholamnezhad Z, Boskabady MH dan Hosseini M. 2014. Effect of *Nigella sativa* on immune response in treadmill exercised rat. *BMC Complementary and Alternative Medicine*, Vol. 14, No. 1, pp. 1–11
- Gholamnezhad Z, Havakhah S dan Boskabady MH. 2016. Preclinical and clinical effects of *Nigella sativa* and its constituent, thymoquinone: A review. *Journal of Ethnopharmacology*, Vol. 190, pp. 372–386.
- Ghoreschi, K., Laurence, A., Yang, X.P., Tato, C.M., McGeachy, M.J., Konkel, J.E., Ramos, H.L., Wei, L., Davidson, T.S., Bouladoux, N., Grainger, J.R., Chen, Q., Kanno, Y., Watford, W.T., Sun, H.W., Eberl, G., Shevach, E.M., Belkaid, Y., Cua, D.J., Chen, W., O’Shea, J.J., 2010. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. *Nature*. 467 (7318), 967–971.
- Goilav B dan Putterman C. 2015 The Role of Anti-DNA Antibodies in the

- Development of Lupus Nephritis: A Complementary, or Alternative, Viewpoint? *Seminar of Nephrology*. Vol. 35, No. 5, pp. 439-43.
- Gottschalk TA, Tsantikos E and Hibbs ML. 2015. Pathogenic inflammation and its therapeutic targeting in systemic lupus erythematosus. *Frontiers in immunology*, Vol. 6, No. 550, pp. 1-14.
- Goyal SN, Prajapati CP, Gore PR, Patil CR, Mahajan UB, Sharma C, Talla SP, Ojha SK. 2017. Therapeutic potential and pharmaceutical development of thymoquinone: A multitargeted molecule of natural origin. *Frontiers in Pharmacology*, Vol. 8, pp. 1–19.
- Greco CM, Nakajima C dan Manzi S. 2013. Updated review of complementary and alternative medicine treatments for systemic lupus erythematosus. *Current rheumatology reports*, Vol. 15, No. 11, p.378-387.
- Grimaldi CM, Cleary J, Selma Dagtas A, Moussai D dan Diamond B. 2002. Estrogen alters thresholds for B cell apoptosis and activation. *Journal of Clinical Investigation*, Vol. 109, No. 12, pp. 1625–1633.
- Gualtierotti R, Marzano AV, Spadari F dan Cugno M. 2019. Main Oral Manifestations in Immune-Mediated and Inflammatory Rheumatic Diseases. *Journal of Clinical Medicine*. Vol. 8. No. 1. pp. 21-40.
- Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J dan Alarcon-Segovia D. 1992. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. *Journal of Rheumatology*, Vol. 19, No. 10, pp. 1551–1558.
- Hadad GH dan Salam RAA. 2012. High-Performance Liquid Chromatography Quantification of Principal Antioxidants in Black seed (*Nigella sativa* L.) Phytopharmaceuticals. *Journal of AOAC International*, Vol. 95, no. 4, pp. 1043- 1047.
- Hadi V, Kheirouri S, Alizadeh M, Khabbazi A dan Hosseini H. 2014. Effects of *Nigella sativa* oil extract on inflammatory cytokine response and oxidative stress status in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial. *Original Research Article*, Vol. 6, No. 1, pp. 34–43.
- Hamijoyo L, Candrianita S, Rahmadi R, Dewi S, Darmawan G, Suryajaya BS, Rainy NR, Hidayat II, Moenardi VN dan Wachjudi RG. 2019. The clinical characteristics of systemic lupus erythematosus patients in Indonesia: a cohort registry from an Indonesia-based tertiary referral hospital. *Lupus*, Vol. 28, No. 13, pp. 1604–1609.
- Haq A, Abdullatif M, Lobo PI, Khabar KSA, Sheth KV dan Al-Sedairy ST. 1995. *Nigella sativa*: effect on human lymphocytes and polymorphonuclear leukocyte phagocytic activity. *Immunopharmacology*, Vol. 30, No. 2, pp. 147–155.
- Haron H, Grace-Lynn C dan Shahar S. 2014. Comparison of physicochemical analysis and antioxidant activities of *Nigella sativa* seeds and oils from Yemen, Iran and Malaysia. *Sains Malaysiana*, Vol. 43, No. 4, pp. 535–542.
- Harry O, Yasin S dan Brunner H. 2018. Childhood-Onset Systemic Lupus Erythematosus: A Review and Update. *Journal of Pediatrics*, Vol. 196, pp. 22-30.

- He YY, Yan Y, Zhang HF, Lin YH, Chen YC, Yan Y, Wu P, Fang JS, Yang SH, Du GH. 2016. Methyl salicylate 2-O- β -D-lactoside alleviates the pathological progression of pristane-induced systemic lupus erythematosus-like disease in mice via suppression of inflammatory response and signal transduction. *Drug Design, Development and Therapy*. Vol. 10. Pp. 3183–3196.
- Hegab DS dan Attia MA. 2015. Decreased circulating T regulatory cells in Egyptian patients with non segmental vitiligo: correlation with disease activity. *Dermatology Research and Practice*. Vol. 2015, pp. 145409.
- Hegab DS, Gamei MM, Saudi WM, Ammo DEA, El Bedewy MM, Elhabian NF. 2014. Role of interleukin-23 in the immunopathogenesis of systemic lupus erythematosus. *Egyptian Journal of Dermatology and Venereology*. Vol. 34. No. 2, pp. 120-125.
- Her Z, Gunawan M, Liu M, Tan SY, Chan XY, Tan WWS, Dharmaraaja S, Fan Y, Ong CB, Loh E dan Chang KTE. 2017. A novel human systemic lupus erythematosus model in humanised mice. *Scientific reports*, Vol. 7, No. 1, p.1-11.
- Hmza AJA, Osman MT, Adnan A dan Omar E. (2013). Immunomodulatory effect of *Nigella sativa* oil in the disease process of type 1 diabetic rats. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*, 4(1), 980–988.
- Hosseinzadeh H, Mollazadeh H dan Afshari AR. 2017. Review on the potential therapeutic roles of *Nigella sativa* in the treatment of patients with cancer: Involvement of Apoptosis. *Journal of Pharmacopuncture*, Vol. 20, No. 3, pp. 158–172.
- Hossen, M. J., Yang, W. S., Kim, D., Aravinthan, A., Kim, J. H., & Cho, J. Y. 2017. Thymoquinone: an IRAK1 inhibitor with in vivo and in vitro anti-inflammatory activities. *Scientific reports*, 7(1), 1-12.
- Huang KP, Zhang ZH, Li RM & Chen X. 2016. The therapeutic effects of the Chinese herbal medicine, Lang Chuang fang granule, on lupus-Prone MRL/lpr mice. *Evidence-based Complementary and Alternative Medicine*, Vol. 2016, pp. 1- 8.
- Huang WM, Stock AD, Mike EV, Herlitz L, Kolbeck R, Putterman C. 2019. Anti-IFNAR treatment does not reverse neuropsychiatric disease in MRL/lpr lupus mice. *Lupus*. Vol. 0, pp. 1-14
- Hussain DA dan Hussain MM. 2016. *Nigella sativa* (black seed) is an effective herbal remedy for every disease except death-a Prophetic statement which modern scientists confirm unanimously: a review. *Advancement in Medicinal Plant Research*, Vol. 4, No. 2, pp.27-57.
- Ichiyama K, Yoshida H, Wakabayashi Y, Chinen T, Saeki K, Nakaya M, Takaesu G, Hori S, Yoshimura A, Kobayashi T. 2008. Foxp3 inhibits ROR γ t-mediated IL-17A mRNA transcription through direct interaction with ROR γ t. *Journal of Biological Chemistry*, Vol. 283, No. 25, pp. 17003–17008.
- Ikhsan M, Hiedayati N, Maeyama K dan Nurwidya F. 2018. *Nigella sativa* as an anti-inflammatory agent in asthma. *BMC Research Notes*, Vol. 11, No. 1, pp. 1–5.

- Ikrom DA, Wira R, Perkasa B, Tiara R dan Wasito. 2014. Studi In Vitro Ekstrak Etanol Daun Kamboja (*Plumeria alba*) sebagai Anti *Aeromonas hydrophila*. *Jurnal Sain Veteriner*, Vol. 32, No. 1, pp. 105–116.
- Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Barlow JE, Lipsky PE. 2010. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. *Arthritis and Rheumatism*, Vol. 62, No. 2, pp. 542–552.
- Indriyanti N dan Garmana AN. 2011. Ekstrak daun cocor bebek (*Kalanchoe pinnata*) untuk terapi preventif lupus pada mencit yang diinduksi dengan 2,6,10,14 tetramethylpentadecane. *Journal of Tropical Pharmacy and Chemistry*, Vol. 1 No. 23, pp. 221-226.
- Indriyati, W., Kusmawati, R., Sriwidodo, S., Hasanah, A. N., & Musfiroh, I. 2016. Karakterisasi Carboxymethyl Cellulose Sodium (Na-CMC) dari Selulosa Eceng Gondok (*Eichhornia crassipes* (Mart.) Solms.) yang Tumbuh di Daerah Jatinangor dan Lembang. *Indonesian Journal of Pharmaceutical Science and Technology*, 3(3), 99-110.
- Iqbal MS, Ahmad A dan Pandey B. 2018. Solvent based optimization for extraction and stability of thymoquinone from *Nigella sativa* Linn. and its quantification using RP-HPLC. *Physiology and Molecular Biology of Plants*, Vol. 24, No. 6, pp. 1209–1219.
- Islam MT, Guha B, Hosen S, Riaz TA dan Shahadat S. 2017. Nigellology: A review on *Nigella sativa*. *MOJ Bioequivalence & Bioavailability*, Vol. 3, No. 6, pp. 27-57.
- Kaleem M, Kirmani D, Asif M, Ahmed Q, Bano B. 2006. Biochemical effects of *Nigella sativa* L seeds in diabetic rats. *Indian Journal of Experimental Biology*, Vol. 44, No. 9, pp. 745-748.
- Kalim H, Handono K, Khalasha T, Pratama MZ, Dantara TWI, Wulandari AP, Albinsaid F, Fitria YN, Mahardika MV. 2017. Immune Modulation Effects of Curcumin in Pristane - induced Lupus Mice. *Indian Journal of Rheumatology*, Vol. 12, No. 2, pp. 86–93.
- Kalim H, Handono K, Prihartini M, Nugraha AS, Sholihah AI, Qonita F, Candra F, Sholihah AI, Pratama MZ. 2018. Regulatory T Cells Compensation Failure Cause the Dysregulation of Immune Response in Pristane Induced Lupus Mice Model. *Malaysian Journal of Medical Sciences*, Vol. 25, No. 3, pp. 17–26.
- Kamal A. 2014. The efficacy of novel B cell biologics as the future of SLE treatment: A review. *Autoimmunity Reviews*, Vol. 13, No. 11, pp.1094–1101.
- Kamal M. 2013. Physicochemical Characteristics, Nutrient Content and Fatty Acid Composition of *Nigella sativa* Oil and Sesame Oil, *Food and Pubcc Health*, Vol. 3, No. 6, pp. 309–314.
- Kasturi S dan Sammaritano LR. 2016. Corticosteroids in Lupus. *Rheumatic Disease Clinics of North America*. 2016;42(1):47-viii.
- Kausar H dan Abidin L MM. 2018. Comparative Assessment of Extraction Methods and Quantitative Estimation of Thymoquinone in the Seeds of *Nigella sativa* L By HPLC. *International Journal of Pharmacognosy and Phytochemical Research*, Vol. 9, No. 12, pp. 1425–1428.

- Kazmi A, Khan MA, Ali H, Dilshad E. 2019. Biotechnological approaches for production of bioactive secondary metabolites in *Nigella sativa*: an up-to-date review. *International Journal of Secondary Metabolite*, Vol. 6, No. 2, pp. 172-195
- Keyhanmanesh R, Saadat S, Mohammadi M, Shahbazfar AA dan Fallahi M. 2015. The protective effect of α -hederin, the active constituent of *Nigella sativa*, on lung inflammation and blood cytokines in ovalbumin sensitized Guinea pigs. *Phytotherapy Research*, Vol. 29, No. 11, pp. 1761–1767.
- Khan SA, Khan AM, Karim S, Kamal MA, Damanhoury GA dan Mirza Z. 2016. Panacea seed “*Nigella*”: A review focusing on regenerative effects for gastric ailments. *Saudi journal of biological sciences*, Vol. 23, No. 4, pp. 542-553.
- Kooti W, Hasanzadeh-Noohi, Z, Sharafi-Ahvazi N, Asadi-Samani M dan Ashtary-Larky D. 2016. Phytochemistry, pharmacology, and therapeutic uses of black seed (*Nigella sativa*). *Chinese journal of natural medicines*, Vol. 14, No. 10, pp.732-745.
- Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB et al. 2007. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. *Nature*. 448: 484–487.
- Kyttaris VC, Zhang Z, Kunchroo vijay K, Oukka M, Tsokos GC. 2010. Cutting Edge: IL-23 Receptor Deficiency Prevents the Development of Lupus Nephritis in C57BL/6–lpr/lpr Mice. *The Journal of Immunology*. Vol. 184, No. 9, pp.1-9.
- La Paglia GMC, Leone, MC, Lepri G, Vagelli R, Valentini E, Alunno A, Tani C. 2017. One year in review 2017: systemic lupus erythematosus. *Clinical Experimental of Rheumatology*, Vol. 35, No. 4, pp. 551-561.
- Larosa M, Zen M, Gatto M, Jesus D, Zanatta E, Iaccarino L, Ines L, Doria A. 2019a. IL-12 and IL-23/Th17 axis in systemic lupus erythematosus. *Experimental Biology and Medicine*, Vol. 244, No. 1, pp. 42–51.
- Lech M dan Anders HJ. 2013. The pathogenesis of lupus nephritis. *Journal of the American Society of Nephrology*, Vol. 24, No. 9, pp.1357-1366.
- Lee HY, Hong YK, Yun HJ, Kim YM, Kim JR dan Yoo WH. 2008. Altered frequency and migration capacity of CD4⁺ CD25⁺ regulatory T cells in systemic lupus erythematosus. *Rheumatology*, Vol. 47, No. 6, pp. 789–794.
- Lee JH, Wang LC, Lin YT, Yang YH, Lin DT dan Chiang BL. 2006. Inverse correlation between CD4⁺ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus. *Immunology*, Vol. 117, No. 2, pp. 280–286.
- Lee, Y., Awasthi, A., Yosef, N., Quintana, F.J., Xiao, S., Peters, A., Wu, C., Kleinewietfeld, M., Kunder, S., Hafler, D.A., Sobel, R.A., Regev, A., Kuchroo, V.K., 2012. Induction and molecular signature of pathogenic T(H)17 cells. *Nature of Immunology*. 13 (10), 991–999.
- Lee YH dan Song GG. 2020. Associations between circulating interleukin-17 levels and systemic lupus erythematosus and between interleukin-17 gene polymorphisms and disease susceptibility: a meta-analysis. *Journal of Rheumatic Diseases*, Vol. 27, No. 1, pp. 37

- Leiss H, Niederreiter B, Bandur T, Schwarzecker B, Blüml S, Steiner G, Ulrich W, Smolen JS dan Stummvoll GH. 2013. Pristane-induced lupus as a model of human lupus arthritis: evolvement of autoantibodies, internal organ and joint inflammation. *Lupus*, Vol. 22, No. 8, pp.778-792.
- Lenz O, Elliot SJ, Stetler-Stevenson WG. 2000. Matrix metalloproteinases in renal development and disease. *JAm Soc Nephrol*. 11:574–581.
- Levy DM dan Kamphuis S, 2012. Systemic lupus erythematosus in children and adolescents. *Pediatric Clinics*, Vol. 59, No. 2, pp.345-364.
- Li C, Ju H, Li Q, Zhou X, Zeng X, He Y, Zeng G, Liu J, Wu C, Yan T, Li W, Cui J, Hu X, Hu JF dan Li T. 2015. Human Umbilical Cord Mesenchymal Stem Cells Suppress Systemic Lupus Erythematosus Lesions by Rebalancing CD4+/CD8+ Cell Population. *Studies on Stem Cells Research and Therapy*. Vol. 1, No. 1, pp. 004-011.
- Li D, Guo B, Wu H, Tan L, Chang C dan Lu Q. 2015. Interleukin-17 in systemic lupus erythematosus: a comprehensive review. *Autoimmunity*, Vol. 48, No. 6, pp.353-361.
- Li Q, Qi B, Duan A, Zhao S, Zhang Y, Zhou X, Dong W, Wang Y, Miao L. 2016. Novel therapies in lupus nephritis associated with regulatory T cells. *International Journal of Clinical and Experimental Medicine*, Vol. 9, No. 11, pp. 20702–20710.
- Li Y, Lee PY dan Reeves WH. 2010. Monocyte and macrophage abnormalities in systemic lupus erythematosus. *Archivum immunologiae et therapiae experimentalis*, Vol. 58, No. 5, pp. 355-364.
- Liberman AC, Budziński AL, Sokn C, Gobbini RP, Steininger A dan Arzt E. 2018. Regulatory and mechanistic actions of glucocorticoids on T and inflammatory cells. *Frontiers in Endocrinology*. Vol. 9, pp. 1-14.
- Luckheeram RV, Zhou R, Verma AD dan Xia B. 2012. CD4 +T cells: Differentiation and functions. *Clinical and Developmental Immunology*, Vol. 2012, pp. 1-12.
- Luijten RKM, Fritsch-Stork RD, Bijlsma JWJ dan Derksen RHW. 2013. The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science. *Autoimmunity Reviews*, Vol. 12, No. 5, pp. 617–628.
- Lyakh L, Trinchieri G, Provezza L, Carra G dan Gerosa F. 2008. Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans. *Immunology Reviews*, Vol. 226, pp. 112–131.
- Mahmood MS, Gilani AH, Khwaja A, Rashid A dan Ashfaq MK. 2003. The in vitro effect of aqueous extract of *Nigella sativa* seeds on nitric oxide production. *Phytotherapy Research*, Vol. 17, No. 8, pp. 921–924.
- Maidhof W dan Hilas O. 2012. Lupus: an overview of the disease and management options. *Pharmacy and Therapeutics*, Vol. 37, No. 4, 240.
- Maitra U, Davis S, Reilly CM, Li L. Differential regulation of Foxp3 and IL-17 expression in CD4 T helper cells by IRAK-1. 2009. *Journal of Immunology*. 2009 May 1;182(9):5763-9
- Majdalawieh AF dan Fayyad MW. 2015. Immunomodulatory and anti-inflammatory action of *Nigella sativa* and thymoquinone: A comprehensive review. *International immunopharmacology*, Vol. 28, No. 1, pp. 295-304.

- Majdalawieh AF dan Fayyad MW. 2016. Recent advances on the anti-cancer properties of *Nigella sativa*, a widely used food additive. *Journal of Ayurveda and integrative medicine*, Vol. 7, No. 3, pp. 173-180.
- Malkiel S dan Diamond B. 2016. Anti-DNA Antibodies, Systemic Lupus Erythematosus Basic, Applied and Clinical Aspects. Academic Press: Massacussette, US
- Mariod AA, Ibrahim RM, Ismail M dan Ismail N. 2009. Antioxidant activity and phenolic content of phenolic rich fractions obtained from black cumin (*Nigella sativa*) seedcake. *Food Chemistry*, Vol. 116, No. 1, pp. 306-312.
- Martin JC, Baeten DL dan Josien R. 2014. Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus. *Clinical immunology*, Vol. 154, No. 1, pp. 1-12.
- McCurdy DK, Bick M, Gatti RA, Naeim F. 1992. Autoantibodies in systemic lupus erythematosus. *Dis Markers*. Vol. 10, No. 1, pp. 37-49.
- McGaha TL dan Madaio MP. 2014. Lupus Nephritis: Animal Modeling of a Complex Disease Syndrome Pathology. *Drug Discovery Today Disease Models*. Vol. 11, pp. 13-18.
- McGeachy, M.J., Bak-Jensen, K.S., Chen, Y., Tato, C.M., Blumenschein, W., McClanahan, T., Cua, D.J., 2007. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell mediated pathology. *Nature of Immunology*. 8 (12), 1390–1397.
- Meka RR, Venkatesha SH, Dudics S, Acharya B dan Moudgil KD. 2015. IL-27-induced modulation of autoimmunity and its therapeutic potential. *Autoimmunity Reviews*, Vol. 14, No. 12, pp. 1131–1141.
- Mellor-Pita S, Citores MJ, Castejon R, Tutor-Ureta P, Yebra-Bango M, Andreu JL, Vargas JA.. 2005. Decrease of regulatory T cells in patients with systemic lupus erythematosus. *Annual of the Rheumatic Disease*. Vol. 65, No. 4, pp. 553-554.
- Mina R. 2011. Response to therapy, damage accrual compared to adult. *North*, Vol. 36, No. 1, pp. 53–80.
- Miyake K, Akahoshi M, dan Nakashima H. 2011. Th subset balance in lupus nephritis. *Journal of Biomedicine and Biotechnology*, Vol. 2011, pp. 1-7.
- Mizui M dan Tsokos GC. 2018. Targeting regulatory T cells to treat patients with systemic lupus erythematosus. *Frontiers in Immunology*, Vol. 9, pp. 1–9.
- Mohamed A, Shoker A, Bendjelloul F, Mare A, Alzrigh M, Benghuzzi H and Desin T. 2003. Improvement of experimental allergic encephalomyelitis (EAE) by thymoquinone; an oxidative stress inhibitor. *Biomedical Science Instrumentation*, Vol. 39, pp. 440–445.
- Mohan C dan Putterman C. 2015. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. *Nature Reviews Nephrology*, Vol. 11, No. 6, pp. 329-41.
- Mok C dan Lau S. 2003. Pathogenesis of systemic lupus erythematosus. *Journal of Clinical and Pathology*, Vol. 56, No. 7, pp. 481-90.
- Mosca M. 2011. Glucocorticoids in systemic lupus erythematosus, *Clinical and Experimental Rheumatology*, Vol. 29, No. 5 (Suppl. 68), pp. 24–27.

- Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M dan Tsokos GC. 2017. Pathogenesis of human systemic lupus erythematosus: a cellular perspective. *Trends in molecular medicine*, Vol. 23, No. 7, pp. 615-635.
- Mudie K, Seifu D, Challa F, Abebe A, Debella A dan Gebregzabher A. 2014. Hepatoprotective activity of aqueous seed extract of *Nigella sativa* against highly active antiretroviral therapy induced hepatotoxicity in rats. *Pharmacology Online*, Vol. 3, pp. 7-10.
- Nadifa S, Achadiyani A, Dharmadji H, Hamijoyo L. 2017. The characteristic of anti-ssDNA and organ system involved in systemic lupus erythematosus patient at Hasan Sadikin General Hospital, Bandung. *Indonesian Journal of Rheumatology*. Vol. 9, No. 1, pp. 231080.
- Nakou M, Papadimitraki E, Fanouriakis A, Bertsias G, Choulaki C, Goulidaki N et al. 2012. Interleukin-21 is increased in active systemic lupus erythematosus patients and contributes to generation of plasma B cells. *Clinical and Experimental Rheumatology*. 31:172–179.
- Nee, LE., Mcmorrow, T., Campbell, E., Slattery, C., & Ryan, MP. 2004. TNF- α and IL-1 β -mediated regulation of MMP-9 and TIMP-1 in renal proximal tubular cells. *Kidney international*. 66(4), 1376-1386.
- Nehar S, Kauser H, Rani P, Alam I. 2015. Effects of *Nigella sativa* seed extract on insulin resistant non-insulin-dependent diabetic guinea pigs. *Am Journla Ethnomedicine*. Vol. 2, No. 1, pp. 58-67.
- Nikakhlagh S, Rahim F, Aryani FHN, Syahpoush A, Brougerdnya MG, Saki N. 2011. Herbal treatment of allergic rhinitis: the use of *Nigella sativa*. *American Journal of Otolaryngology*. Vol. 32, No. 5, pp. 402-407.
- Nobee A dan Justiz-Vaillant A. 2016. Levels of Interleukin-17 and Interleukin-23 in Patients with Systemic Lupus Erythematosus (SLE) in Trinidad and Tobago. *Immunochemistry and Immunopathology* Vol. 02, No. 01, pp. 2-4.
- O’Keefe AW, Halbrich M, Ben-Shoshan M, McCusker C. 2016. Primary immunodeficiency for the primary care provider. *Paediatrics and Child Heathl*. Vol. 21, No. 2, pp. e10-e14.
- Onifade AA, Jewell AP dan Adedeji WA. 2013. *Nigella sativa* concoction induced sustained seroreversion in HIV patient. *African Journal of Traditional and Complementer Alternative Medicine*, Vol. 10, No. 5, pp. 332-335.
- Onishi RM dan Gaffen SL. 2010. Interleukin-17 and its target genes: Mechanisms of interleukin-17 function in disease. *Immunology*, Vol. 129, No. 3, pp. 311–321.
- Pan L, Lu MP, Wang JH, Xu M, dan Yang SR. 2019. Immunological pathogenesis and treatment of systemic lupus erythematosus. *World Journal of Pediatrics*. Vol. 16, No. 1, pp. 19-30.
- Pan Q, Liu Z, Liao S, Ye L, Lu, X, Chen X, Li Z, Li X, Xu YZ, Liu H. 2019. Current mechanistic insights into the role of infection in systemic lupus erythematosus. *Biomedicine and Pharmacotherapy*, Vol. 117, pp. 109122.
- Pannu A, Goyal RK, Ojha S, Nandave M. 2019. Therapeutic Potential of Thymoquinone in Treatment of Rheumatoid Arthritis and Related Autoimmune Diseases. 2nd ed. Elsevier Inc: Amsterdam, Netherlands

- Panther, E. J., Ren, J., Cabana-Puig, X., Abdelhamid, L., Swartwout, B., Luo, X. M., & Reilly, C. M. 2020. The Effect of Dietary Fiber Intake on Systemic Lupus Erythematosus (SLE) Disease in NZB/W Lupus Mice. *Journal of Clinical and Cellular Immunology*. 2020: 141-6
- Parks CG, Santos A, Barbhैया M dan Costenbader KH. 2017. Understanding the role of environmental factors in the development of systemic lupus erythematosus. *Best Practice and Research: Clinical Rheumatology*, Vol. 31, No. 3, pp. 306–320.
- Parris K. 2003. Th1/Th2 balance: The hypothesis, its limitations, and implications for health and disease. *Alternative Medicine Review*, Vol. 8, No. 3, pp. 223–246.
- Patavito TBD. 2001. Natural medicine and nutritional therapy as an alternative treatment in systemic lupus erythematosus. *Alternative Medicine Review*, Vol. 6, No. 5, pp. 460–471.
- Pathak S dan Mohan C. 2011. Cellular and molecular pathogenesis of systemic lupus erythematosus: lessons from animal models. *Arthritis research dan therapy*, Vol. 13, No. 5, pp. 241-250.
- Peng J, Yang XO, Chang SH, Yang J dan Dong C. 2010. IL-23 signaling enhances Th2 polarization and regulates allergic airway inflammation. *Cell Research*, Vol. 20, No. 1, pp. 62–71.
- Perhimpunan Reumatologi Indonesia, 2011. Rekomendasi Perhimpunan Reumatologi Indonesia untuk Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik. Perhimpunan Reumatologi Indonesia. Jakarta.
- Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae S-C, Hanly JG, Sanchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, M, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks JrAG, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin JrG dan Magder LS. 2012. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with Systemic Lupus Erythematosus. *Arthritis and Rheumatism*, Vol. 64, No. 8, pp. 2677–2686.
- Pinheiro SVB, Dias RF, Fabiano RCG, Araujo SA, Silva ACS. 2019. Pediatric lupus nephritis. *Braz. Journal of Nephrology* Vol. 41, No. 2, pp. 252-65.
- Polansky JK, Floess S, Freyer J, Hamann A dan Huehn J. 2008. Epigenetic regulation of FoxPp3 expression in regulatory T cells. Dalam *The Epigenetics of Autoimmune Diseases*. Zouali M. (Ed). John Wiley & Sons Ltd, New York
- Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L dan Cooper GS. 2010. Understanding the epidemiology and progression of systemic lupus erythematosus. *Seminars in arthritis and rheumatism*. Vol. 39, No. 4, pp. 257-268. WB Saunders. New York.

- Pons-Estel GJ, Ugarte-Gil MF dan Alarcón GS. 2017. Epidemiology of systemic lupus erythematosus. *Expert review of clinical immunology*, Vol. 13, No. 8, pp. 799-814.
- Postal M, Costallat LT dan Appenzeller S. 2012. Biological therapy in systemic lupus erythematosus. *International Journal of Rheumatology*, Vol. 2012, pp. 1-9.
- Putri RDA dan Kurniyati Z. 2016. Effect of sodium chloroacetate towards the Synthesis of CMC (Carboxymethyl Cellulose) from Durian (Durio zibethinus) peel cellulose. *International Journal of Innovative Research in Advanced Engineering* . Vol. 3, No. 03, Volume 3, pp. 28-32.
- Puwiprom H, Hirankarn N, Sodsai P, Avihingsanon Y, Wongpiyabovorn J, dan Palaga T. 2010. Increased interleukin-23 receptor+T cells in peripheral blood mononuclear cells of patients with systemic lupus erythematosus. *Arthritis Research and Therapy*, Vol. 12, No. 6, pp. R215.
- Qi S, Chen Q, Xu D, Xie N dan Dai Y. 2018. Clinical application of protein biomarkers in lupus erythematosus and lupus nephritis. *Lupus*, Vol. 27, No. 10, pp. 1582–1590.
- Qu H, Bian W, Xu Y. 2014. A novel NF - κ B inhibitor , DHMEQ , ameliorates pristane - induced lupus in mice. Vol. 2014, No. 7, pp. 100-104
- Quan TE, Roman RM, Rudenga, BJ, Holers VM dan Craft JE. 2010. Epstein-Barr virus promotes interferon- α production by plasmacytoid dendritic cells. *Arthritis dan Rheumatism*, Vol. 62, No. 6, pp. 1693-1701.
- Reeves WH, Lee PY, Weinstein JS, Satoh M. dan Lu, L. 2009. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. *Trends in immunology*, Vol. 30, No. 9, pp. 455-464.
- Rekvig OP. 2015. Anti-dsDNA antibodies as a classification criterion and a diagnostic marker for systemic lupus erythematosus: critical remarks. *Clinical & Experimental Immunology*, Vol. 179, No. 1, pp. 5-10.
- Rhen T dan Cidlowski JA. 2005. Antiinflammatory action of glucocorticoids - New mechanisms for old drugs. *New England Journal of Medicine*, Vol. 353, No. 16, pp. 1711–1723.
- Rice JB, White AG, Scarpati LM, Wan G dan Nelson WW. 2017. Long-term systemic corticosteroid exposure: a systematic literature review. *Clinical therapeutics*, Vol. 39, No. 11, pp. 2216-2229.
- Richard ML dan Gilkeson G. 2018. Mouse models of lupus: What they tell us and what they don't. *Lupus Science and Medicine*, Vol. 5, pp. 1-7.
- Richards HB, Satoh M, Shaw M, Libert C, Poli V, Reeves WH. 1998. Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. *Journal of Experimental Medicine*. Vol. 188, No. 5, pp. 985-90.
- Richez C, Blanco P, Rifkin I, Moreau JF, dan Schaeffer T. 2011. Role for toll-like receptors in autoimmune disease: The example of systemic lupus erythematosus. *Joint Bone Spine*, Vol. 78, No. 2, pp. 124–130.
- Rojas M, Restrepo-Jiménez P, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Ramírez-Santana C, Leung PSC, Ansari A, Gershwin ME, Anaya JM. 2018. Molecular mimicry and autoimmunity. *Journal of Autoimmunity*, Vol. 95, pp. 100-123.

- Rojas M, Rodríguez Y, Leon KJ, Pacheco Y, Acosta-Ampudia Y, Monsalve DM, Ramírez-Santana C, Anaya J. 2018. Cytokines and Inflammatory Mediators in Systemic Lupus Erythematosus, *EMJ Rheumatology*. Vol. 5, No. 1, pp. 83-92.
- Rönnblom L dan Elkon KB. 2010. Cytokines as therapeutic targets in SLE. *Nature Reviews Rheumatology*, Vol. 6, No. 6, pp. 339–347.
- Rose T dan Dörner T. 2017. Drivers of the immunopathogenesis in systemic lupus erythematosus. *Best Practice and Research: Clinical Rheumatology*, Vol. 31, No. 3, pp. 321–333.
- Rother N dan Van der Vlag J. 2015. Disturbed T cell signaling and altered Th17 and regulatory T cell subsets in the pathogenesis of systemic lupus erythematosus. *Frontiers of Immunology*. Vol. 6, No. NOV, pp. 1-10.
- Rottman JB dan Willis CR. 2010. Mouse models of systemic lupus erythematosus reveal a complex pathogenesis. *Veterinary pathology*, Vol. 47, No. 4, pp. 664-676.
- Ruiz-Irastorza G, Danza A dan Khamashta M. 2012. Review Glucocorticoid use and abuse in SLE, *Rheumatology*, Vol. 51, No. 7, pp. 1145–1153.
- Saber NZ, Maroof SH, Soliman DA, Fathi MS. 2017. Expression of T helper 17 cells and interleukin 17 in lupus nephritis patients. *Egypt Rheumatology*. Vol. 39, No. 3, pp. 151-157.
- Sabzghabae AM, Dianatkah M, Sarrafzadegan N, Asgary S dan Ghannadi A. 2012. Clinical evaluation of *Nigella sativa* seeds for the treatment of hyperlipidemia: a randomized, placebo controlled clinical trial. *Medical Archives*, Vol. 66, No. 3, pp. 198-200.
- Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P dan Yamaguchi T. 2009. Regulatory T cells: How do they suppress immune responses? *International Immunology*, Vol. 21, No. 1), pp. 1105–1111.
- Salem AM, Bamosa AO, Qutub HO, Kumar R, Badar A, Elnour A, Afzal MN, 2017. Effect of *Nigella sativa* supplementation on lung function and inflammatory mediators in partly controlled asthma: a randomized controlled trial. *Annals of Saudi Medicine*. Vol. 37, pp. 514–521.
- Salem ML. 2005. Immunomodulatory and therapeutic properties of the *Nigella sativa* L. seed. *International Immunopharmacology*, Vol. 5, pp. 1749–1770.
- Salgado ADZ dan Herrera-Diaz C. 2012. Lupus nephritis: An overview of recent findings. *Autoimmune Diseases*, Vol. 1, No. 1. pp. 1-21.
- Salido O dan Reyes M. 2010. Epidemiology of systemic lupus erythematosus in Asia. *Arthritis Care Research (Hoboken)*, Vol. 64, No. 2, pp. 159-68.
- Samotij D dan Reich A. 2019. Biologics in the treatment of lupus erythematosus: A critical literature review. *BioMed Research International*, Vol. 2019, pp. 1-17.
- Sandi EO. 2012 “Perbedaan penggunaan bahan pengikat Na-CMC dan HPMC terhadap sifat fisik, kimia dan uji hedonik sediaan pasta gigi enzim papain Pepaya (*Carica papaya* L.)”. Skripsi. Universitas Sebelas Maret: Surakarta
- Sang A, Zheng YY dan Morel L. 2014. Contributions of B cells to lupus pathogenesis. *Molecular immunology*, Vol. 62, No. 2, pp. 329-338.

- Sanz I dan Lee FEH. 2010. B cells as therapeutic targets in SLE. *Nature Reviews Rheumatology*, Vol. 6, No. 6, pp. 326-337.
- Satoh M, Richards HB, Shaheen VM, Yoshida H, Shaw M, Naim JO, Wooley PH, Reeves WH. 2000. Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. *Clinical and Experimental Immunology*. Vol. 121, No. 2, pp. 399–405
- Savarese E, Steinberg C, Pawar RD, Reindl W, Akira S, Anders H-J, Krug A. 2008. Requirement of toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. *Arthritis and Rheumatology*. Vol 58, No. 4, pp. 1107–1115.
- Sawalha AH, Kaufman KM, Kelly JA, Adler AJ, Aberle T, Kilpatrick J et al. 2008. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. *AnnRheumDis*. 67: 458–461.
- Schreiber J, Eisenberger U dan de Groot K. 2019. Lupus nephritis. *Internist*, Vol. 60, No. 5, pp. 468–477.
- Seki R dan Nishizawa K. 2016. Factors regulating Th17 cells: A review. *Biomedical Research and Clinical Practice*, Vol. 1, No. 4, pp. 126–147.
- Seredkina N, Horvei KD, Pedersen HL, Rekvig OP dan Thiyagarajan D. 2016. Future Perspectives on Pathogenesis of Lupus Nephritis. *The American Journal of Pathology*, Vol. 186, No. 11, pp. 2772–2782.
- Shabana A, El-Menyar A, Asim M, Al-Azzeh H dan Al Thani H. 2013. Cardiovascular benefits of black cumin (*Nigella sativa*). *Cardiovascular Toxicology*, Vol. 13, No. 1, pp. 9–21.
- Shahba A, Esheba NE, Fooda AA, El-Dardiry S, Wagih A dan El-Deeb O. 2015. *Effect of Nigella sativa and Vitamin E on Some Oxidative / Nitrosative Biomarkers in Systemic Lupus Erythematosus Patients*. Life Science Journal, Vol. 12, No. 7, pp. 157–162.
- Shaheen VM, Satoh M, Richards HB, Yoshida H, Shaw M, Jennette JC, Reeves WH. 1999. Immunopathogenesis of environmentally induced lupus in mice. *Environ Health Perspect*. Vol. 107, No. SUPPL. 5, pp. 723-727.
- Sharma NK, Ahirwar D, Jhade D dan Gupta S. 2009. Medicinal and pharmacological potential of *Nigella sativa*: a review. *Ethnobotanical Leaflets*, Vol. 13, No. 7, pp. 11.
- Sheba SH, Djuhaeni H, Setiabudiawan B, Sunjaya DK, Mutyara K dan Rinawan FR. 2018. Kepatuhan Minum Obat Pada Pasien Lupus Eritematosus Sistemik di RSUP Dr. Hasan Sadikin Bandung. *Majalah Kedokteran Bandung*, Vol. 50, No. 1, pp. 21-28.
- Shin W, Lee HT, Lim H, Lee SH, Son JY, Lee JU, Yoo KY, Ryu SE, Rhie J, Lee JY, Heo YS. 2018. BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus. *Nature Communications*. Vol. 9, No. 1200, pp. 1-11.
- Sinha A dan Bagga A. 2008. Pulse steroid therapy. *Indian Journal of Pediatrics*, Vol. 75, No. 10, pp. 1057–1066.
- Smatti MK, Cyprian FS, Nasrallah GK, Al-Thani AA, Almishal RO dan Yassine HM. 2019. Viruses and autoimmunity: A review on the potential interaction and molecular mechanisms. *Viruses*, Vol. 11, No. 8, pp. 1–18.

- Srinivasan K. 2018. Cumin (*Cuminum cyminum*) and black cumin (*Nigella sativa*) seeds: traditional uses, chemical constituents, and nutraceutical effects. *Food Quality and Safety*, Vol. 2, No. 1, pp. 1–16.
- Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS and Ley K. 2005. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. *Immunity*, Vol. 22, No. 3, pp. 285-294.
- Steinmann-niggli K, Ziswiler R, Kung M, Marti HP. 1998. Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis. *JAm Soc Nephrol*. 9:397–407.
- Stichweh D, Arce E dan Pascual V. 2004. Update on pediatric systemic lupus erythematosus. *Current Opinion in Rheumatology*, Vol. 16, No. 5, pp. 577–587.
- Su DL, Lu ZM, Shen MN, Li X dan Sun LY. 2012. Roles of pro and anti-inflammatory cytokines in the pathogenesis of SLE. *BioMed Research International*, Vol. 2012, pp. 1-15.
- Su H, Lei CT dan Zhang C. 2017. Interleukin-6 signaling pathway and its role in kidney disease: An update. *Frontiers in Immunology*, Vol. 8, pp. 1–10.
- Sulistiawati F dan Radji M. 2017. Potensi Pemanfaatan *Nigella sativa* L. sebagai Imunomodulator dan Antiinflamasi. *Pharmaceutical Sciences and Research*. Vol. 1, No. 2, pp. 65-77.
- Summers, S. A., Odobasic, D., Khouri, M. B., Steinmetz, O. M., Yang, Y., Holdsworth, S. R., & Kitching, A. R. 2014. Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane. *Clinical and experimental immunology*. Vol.176, No. 3, pp. 341–350.
- Susanti N, Barlianto W, Kalim H, Kusuma HMSC. 2013. Asthma clinical improvement and reduction in the number of immunotherapy house dust mite and adjuvant probiotics and / or *Nigella sativa* powder in mild asthmatic children. *IOSR Journal of Dental and Medical Sciences*. Vol. 7, No. 3, pp. 50-59.
- Tajmiri S, Abbasalizad M dan Dehghan P. 2016. *Nigella sativa* treatment and serum concentrations of thyroid hormones, transforming growth factor b (TGF- b) and interleukin 23 (IL-23) in patients with Hashimoto's Thyroiditis. *European Journal of Integrative Medicine*, Vol. 8, No. 4, pp. 576-580.
- Talaat RM, Mohamed SF, Bassyouni IH, Raouf AA. 2015. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity. *Cytokine*. Vol. 72. No. 2, pp.146-153.
- Tamirou F, Arnaud L, Talarico R, Scirè CA, Alexander T, Amoura Z, Avcin T, Bortoluzzi A, Cervera R, Conti F, Cornet A, Devilliers H, Doria A, Frassi M, Fredi M, Govoni M, Houssiau F, Lladò A, Macieira C, Martin T, Massaro L, Moraes-Fontes MF, Pamfil C, Paolino S, Tani C, Tas SW, Tektonidou M, Tincani A, Van Vollenhoven RF, Bombardieri S, Burmester G, Fonseca JE, Galetti I, Hachulla E, Mueller-Ladner U, Schneider M, Smith V, Cutolo M, Mosca M, Costedoat-Chalumeau N. 2018. Systemic lupus erythematosus: State of the art on clinical practice guidelines. *RMD Open*, Vol. 4, No. 2, pp. 1–6.

- Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis & Rheumatism*, Vol. 25, No. 11, pp. 1271–1277.
- Tanaka T, Narazaki M dan Kishimoto T. 2014. IL-6 in Inflammation, Immunity, and Disease, *Cold Spring Harbor Perspectives in Biology*. Vol. 6, No. 10, pp. a016295 - a016341.
- Tang C, Chen S, Qian H, Huang W. 2012. Interleukin-23: As a drug target for autoimmune inflammatory diseases. *Immunology*. Vol. 135, No. 2, pp.112-124.
- Teng MWL, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper, AM, Cua JD. 2015. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. *Nature Medicine*, Vol. 21, No. 7. Pp. 719-729.
- Thamer, M. A. E., Hernán, M. A., Zhang, Y. I., Cotter, D., & Petri, M. 2009. Prednisone, lupus activity, and permanent organ damage. *The Journal of rheumatology*, 36(3), 560-564.
- Toussirost É. 2012. The IL-23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. *Inflamm Allergy - Drug Targets*. Vol. 11, No. 2, pp. 159-168.
- Umar S, Hedaya O, Singh AK dan Ahmed A. 2015. Thymoquinone inhibits TNF- α -induced inflammation and cell adhesion in rheumatoid arthritis synovial fibroblasts by ASK1 regulation. *Toxicology and Applied Pharmacology*, Vol. 287, No. 3, pp. 299–305.
- Umar S, Zargan J, Umar K, Ahmad S, Katiyar CK, Khan HA. 2012. Modulation of the oxidative stress and inflammatory cytokine response by thymoquinone in the collagen induced arthritis in Wistar rats. *Chemico-Biological Interactions*. Vol. 197, No. 1, pp. 40-46.
- Van Nieuwenhuijze A dan Liston A. 2015. The Molecular Control of Regulatory T Cell Induction. *Progress in Molecular Biology and Translational Science* (1 ed., Vol. 136). Elsevier Inc. Amsterdam, Netherlands
- Vincent FB, Morand EF, Schneider P dan Mackay F. 2014. The BAFF/APRIL system in SLE pathogenesis. *Nature Reviews Rheumatology*, Vol. 10, No. 6, pp. 365-373.
- Waite JC dan Skokos D. 2012. Th17 response and inflammatory autoimmune diseases. *International Journal of Inflammation*, Vol. 2012, pp. 1-10.
- Waldman M dan Madaio MP. 2005. Pathogenic autoantibodies in lupus nephritis. *Lupus*. Vol. 14, pp. 19 – 24.
- Wang X dan Xia Y. 2019. Anti-double stranded DNA antibodies: Origin, pathogenicity, and targeted therapies. *Frontiers in Immunology*, Vol. 10, pp. 1–14.
- Webb R, Merrill JT, Kelly JA, Sestak A, Kaufman KM, Langefeld CD et al. 2009. A polymorphism within IL21R confers risk for systemic lupus erythematosus. *Arthritis Rheumatology*. 60: 2402–2407
- Wen Z, Xu L, Xu W, Yin Z, Gao X, Xiong S. 2013. Interleukin-17 Expression Positively Correlates with Disease Severity of Lupus Nephritis by Increasing Anti-Double-Stranded DNA Antibody Production in a

- Lupus Model Induced by Activated Lymphocyte Derived DNA. *PLoS One*. Vol. 8, No. 3, pp. 1-10.
- Wenderfer SE dan Eldin KW. 2019. Lupus Nephritis. *Pediatric Clinics of North America*, Vol. 66, No. 1, pp. 87–99.
- Wu H, Fu S, Zhao M, Lu L dan Lu, Q. (2017). Dysregulation of cell death and its epigenetic mechanisms in systemic lupus erythematosus. *Molecules*, Vol. 22, No. 1, pp. 1–12.
- Xiong W dan Lahita RG. 2011. Novel treatments for systemic lupus erythematosus. *Therapeutic Advances in Musculoskeletal Disease*. Vol. 3, No. 5, pp. 255-266.
- Xuan NT, Shumilina E, Qadri SM, FriedrichGötz dan Lang F. 2010. Effect of Thymoquinone on Mouse Dendritic Cells. *Cellular Physiology and Biochemistry*, Vol. 25, pp. 307-314.
- Yan, S. X., Deng, X. M., Wang, Q. T., Sun, X. J., & Wei, W. 2015. Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice. *Acta Pharmacologica Sinica*, 36(11), 1367-1376.
- Yang J, Chu Y, Yang X Gao D, Zhu L, Yang X, Wan L dan Li M. 2009. Th17 and natural treg cell population dynamics in systemic lupus erythematosus. *Arthritis and Rheumatology*. Vol. 60, No. 5, pp.1472-1483
- Yang J, Sundrud MS, Skepner J, Yamagata T. 2014. Targeting Th17 cells in autoimmune diseases. *Trends in Pharmacological Sciences*. Vol. 35, No. 10, pp. 493-500.
- Yang W, Bhandaru M, Pasham V, Zelenak C, Jilani K dan Rotte A. 2012. Cellular physiology and biochemistry effect of thymoquinone on cytosolic ph and na/h exchanger activity in mouse dendritic cells. *Cellular Physiology and Biochemistry*, Vol. 29, pp. 21–30.
- Yap DYH dan Lai KN. 2010. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. *Journal of Biomedicine and Biotechnology*, Vol. 2010, pp. 1–10.
- Yarnell E dan Abascal K. 2008. Lupus erythematosus and herbal medicine. *Alternative and Complementary Therapies*. Vol. 14, No. 1, pp. 9-12.
- Yarnell E dan Abascal K. 2011. *Nigella sativa*: holy herb of the Middle East. *Alternative and Complementary Therapies*. Vol. 17, No. 2, pp. 99-105.
- Yeoh SA, Dias SS, dan Isenberg DA. 2018. Advances in systemic lupus erythematosus. *Medicine*, Vol. 46, No. 2, pp. 84–92.
- Yimer EM, Tuem KB, Karim A, Ur-Rehman N dan Anwar F. 2019. *Nigella sativa* L. (black cumin): a promising natural remedy for wide range of illnesses. *Evidence-based Complementary and Alternative Medicine*, Vol. 2019, pp. 1-17.
- Zaoui A, Cherrah Y, Mahassini N, Alaoui K, Amarouch H dan Hassar M. 2002. Acute and chronic toxicity of *Nigella sativa* fixed oil. *Phytomedicine*, Vol. 9(1), pp. 69–74.
- Zhang X, Zhao L, Yang H dan Li Y. 2010. Increased CD4+CD25-Foxp3+ T Cells in New-onset Systemic Lupus Erythematosus Patients are Phenotypically and Functionally Different from Classic Regulatory T Cells. *Clinical Immunology*, Vol. 135, pp. S22–S23.

- Zhang Z, Kyttaris VC dan Tsokos GC. 2009. The Role of IL-23/IL-17 Axis in Lupus Nephritis. *The Journal of Immunology*, Vol. 183, No. 5, pp. 3160–3169.
- Zhao H, Liao X dan Kang Y. 2017. Tregs: Where we are and what comes next? *Frontiers in Immunology*, Vol. 8, No. 1578, pp. 1-14.
- Zhong LLD, Bian ZX, Gu JH, Zhou X, Tian Y, Mao JC, dan Chen XJ. 2013. Chinese herbal medicine (zi shen qing) for mild-to-moderate systematic lupus erythematosus: a pilot prospective, single-blinded, randomized controlled study. *Evidence-Based Complementary and Alternative Medicine*. Vol. 2013, pp. 1-10.
- Zickert A, Amoudruz P, Sundström Y, Rönnelid J, Malmström V dan Gunnarsson I. 2015. IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment. *BMC Immunology*. Vol. 16, No. 7, pp. 1-10